Completed PHASE1 INTERVENTIONAL 1-arm NCT02518958

A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab (PRIMETIME)

A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)

Sponsor: EpicentRx, Inc.

Conditions Lymphoma Malignant Solid Tumor

Interventions Nivolumab RRx-001

Updated 8 times since 2017 Last updated: Nov 14, 2019 Started: Jul 21, 2015 Primary completion: May 17, 2016 Completion: Sep 12, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02518958, this PHASE1 trial focuses on Lymphoma and Malignant Solid Tumor and remains completed. Sponsored by EpicentRx, Inc., it has been updated 8 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Dec 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jun 2018 — Dec 2019 [monthly]

Active Not Recruiting PHASE1

▶ Show 3 earlier versions

Aug 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Feb 2017 — Aug 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EpicentRx, Inc.

Data source: EpicentRx, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States